- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Taysha Gene Therapies Inc (TSHA)
Taysha Gene Therapies Inc stock price live, this page displays NASDAQ TSHA stock exchange data. View the TSHA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Taysha Gene Therapies Inc real time stock price chart below.
What Is the Taysha Gene Therapies Inc Stock Price Today?
The Taysha Gene Therapies Inc stock price today is 2.720.
What Is the Stock Symbol for Taysha Gene Therapies Inc?
The stock symbol for Taysha Gene Therapies Inc is ""TSHA.""
What Stock Exchange Does Taysha Gene Therapies Inc Trade On?
Taysha Gene Therapies Inc is listed and trades on the NASDAQ stock exchange.
Is Taysha Gene Therapies Inc a Good Stock to Buy?
Determining whether Taysha Gene Therapies Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TSHA quote. (ISIN: US8776191061)
What Is the Taysha Gene Therapies Inc Stock Price Today?
The Taysha Gene Therapies Inc stock price today is 2.720.
What Is the Stock Symbol for Taysha Gene Therapies Inc?
The stock symbol for Taysha Gene Therapies Inc is ""TSHA.""
What Stock Exchange Does Taysha Gene Therapies Inc Trade On?
Taysha Gene Therapies Inc is listed and trades on the NASDAQ stock exchange.
Is Taysha Gene Therapies Inc a Good Stock to Buy?
Determining whether Taysha Gene Therapies Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TSHA quote. (ISIN: US8776191061)
2.720
-0.090(-3.20%)
Closed·
After Hours
2.768+0.048(+1.77%)
·
Fair Value
An estimate of a Taysha Gene's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.700
2.845
52 wk Range
1.050
3.310
TSHA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 3 days
1/2
Fair Value
An estimate of a Taysha Gene's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.7002.845
52 wk Range
1.0503.310
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
TSHA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Taysha Gene's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
8.318
Upside
+205.82%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Taysha Gene Therapies Inc Company Profile
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Taysha Gene Therapies Inc SWOT Analysis
Gene Therapy Promise | Taysha's TSHA-102 shows potential in treating Rett syndrome, with positive preliminary data and strategic clinical trial advancements boosting investor confidence |
Financial Fortification | Recent $76.8M offering extends cash runway to Q4 2026, strengthening Taysha's position to fund ongoing trials and operational expenses without immediate financial pressure |
Regulatory Roadmap | RMAT designation and upcoming regulatory meetings could expedite TSHA-102's approval process, with key milestones expected to provide clarity on the path to market |
Market Opportunity | Analysts set price targets ranging from $5 to $8 per share, reflecting optimism about Taysha's potential in the estimated $2 billion+ Rett syndrome treatment market |
Taysha Gene Therapies Inc Earnings Call Summary for Q1/2025
- Q1 2025 EPS of -$0.08 beat expectations; revenue of $2.3M exceeded forecast by $390,000
- Stock surged 10.13% pre-market to $2.61; company maintains strong liquidity with cash exceeding debt
- Significant progress reported in gene therapy trials for Rett syndrome; cash runway secured through Q4 2026
- Plans to initiate Part B of pivotal trial for TATIA-102 in late 2025/early 2026; exploring European market expansion
- Analysts maintain strong buy consensus with price targets ranging from $5 to $9 per share
Last Updated: 15/05/2025, 14:42
Read Full TranscriptCompare TSHA to Peers and Sector
Metrics to compare | TSHA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTSHAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.7x | −1.0x | −0.5x | |
PEG Ratio | −0.12 | −0.05 | 0.00 | |
Price/Book | 10.6x | 2.2x | 2.6x | |
Price / LTM Sales | 80.8x | 8.9x | 3.3x | |
Upside (Analyst Target) | 194.1% | 318.8% | 43.5% | |
Fair Value Upside | Unlock | 7.6% | 6.8% | Unlock |
Analyst Ratings
12 Buy
0 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 8.318
(+205.82% Upside)
Earnings
Latest Release
May 15, 2025
EPS / Forecast
-0.08 / -0.09
Revenue / Forecast
2.30M / 1.91M
People Also Watch
FAQ
What Stock Exchange Does Taysha Gene Trade On?
Taysha Gene is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Taysha Gene?
The stock symbol for Taysha Gene is "TSHA."
What Is the Taysha Gene Market Cap?
As of today, Taysha Gene market cap is 583.88M.
What Is Taysha Gene's Earnings Per Share (TTM)?
The Taysha Gene EPS (TTM) is -0.33.
When Is the Next Taysha Gene Earnings Date?
Taysha Gene will release its next earnings report on 11 Aug 2025.
From a Technical Analysis Perspective, Is TSHA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Taysha Gene Stock Split?
Taysha Gene has split 0 times.
How Many Employees Does Taysha Gene Have?
Taysha Gene has 73 employees.
What is the current trading status of Taysha Gene (TSHA)?
As of 09 Aug 2025, Taysha Gene (TSHA) is trading at a price of 2.72, with a previous close of 2.81. The stock has fluctuated within a day range of 2.70 to 2.85, while its 52-week range spans from 1.05 to 3.31.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.